Price
$9.13
Increased by +4.46%
Dollar Volume (20D)
1.09 M
ADR%
6.6
Earnings Report Date (estimate)
May 6, 24
Shares Float
24.04 M
Shares Outstanding
49.26 M
Shares Short
2.53 M
Market Cap.
430.53 M
Beta
0.29
Price / Earnings
N/A
20D Range
7.21 9.72
50D Range
7.21 9.72
200D Range
5.99 13.5
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 23 -0.48
Increased by +11.11%
-0.52
Increased by +7.69%
Aug 9, 23 -0.48
Decreased by -4.35%
-0.49
Increased by +2.04%
May 11, 23 -0.46
Decreased by -4.55%
-0.54
Increased by +14.81%
Mar 15, 23 -0.55
Increased by +78.09%
-0.52
Decreased by -5.77%
Nov 10, 22 -0.54
Decreased by -116%
-0.51
Decreased by -5.88%
Aug 11, 22 -0.46
Increased by +98.39%
-0.46
May 12, 22 -0.44
Increased by +97.87%
-0.44
Mar 23, 22 -2.51
Increased by +84.92%
-0.39
Decreased by -543.59%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-18.51 M
Decreased by -17.56%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-18.3 M
Decreased by -39.47%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-15.16 M
Decreased by -17.89%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-41.81 M
Decreased by -259.36%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-15.75 M
Decreased by -78.17%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-13.12 M
Decreased by -48.22%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-12.86 M
Decreased by -116.96%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-11.63 M
Decreased by -137.09%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.